Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).

ABSTRACT: The resilience of high-grade gliomas (HGGs) against conventional chemotherapies is due to their heterogeneous genetic landscape, adaptive phenotypic changes, and immune escape mechanisms. Innovative immunotherapies have been developed to counteract the immunosuppressive capability of gliomas. Nevertheless, further research is needed to assess the efficacy of the immuno-based approach. The aim of this study is to review the newest immunotherapeutic approaches for glioma, focusing on the drug types, mechanisms of action, clinical pieces of evidence, and future challenges. A PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis)-based literature search was performed on PubMed/Medline and ClinicalTrials.gov databases using the keywords "active/adoptive immunotherapy," "mono

SUBMITTER: Giotta Lucifero A 

PROVIDER: S-EPMC8003180 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature